Advanced search
Publication Cover
Infection and Drug Resistance Volume 17, 2024 - Issue
Submit an article Journal homepage
108
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient

Yoko Tanino1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan;2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Keisuke Nishioka1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Chie Yamamoto2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Yohei Watanabe1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan;3 JST, MIRAI, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-8305-6952View further author information
ORCID Icon,
Tomo Daidoji1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan;4 School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido, JapanView further author information
,
Masataka Kawamoto5 Department of Forensics Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Sayaka Uda6 Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Shoko Kirito1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Yuta Nakagawa2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Yu Kasamatsu2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Yoshiyuki Kawahara7 Kyoto Prefectural Institute of Public Health and Environment, Kyoto, JapanORCID Iconhttps://orcid.org/0009-0009-8134-9098View further author information
ORCID Icon,
Yuri Sakai7 Kyoto Prefectural Institute of Public Health and Environment, Kyoto, JapanORCID Iconhttps://orcid.org/0009-0008-5745-0922View further author information
ORCID Icon,
Shuji Nobori8 Department of Organ Transplantation and General Surgery, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Tohru Inaba2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanORCID Iconhttps://orcid.org/0000-0002-1595-8524View further author information
ORCID Icon,
Bon Ota9 Department of Emergency Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Naohisa Fujita7 Kyoto Prefectural Institute of Public Health and Environment, Kyoto, JapanView further author information
,
Atsushi Hoshino10 Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
,
Yoko Nukui2 Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto, JapanView further author information
&
Takaaki Nakaya1 Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, JapanCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-7513-6186View further author information
ORCID Icon show all
Pages 531-541 | Received 06 Sep 2023, Accepted 22 Jan 2024, Published online: 08 Feb 2024

References

  • Birnie E, Biemond JJ, Appelman B, et al. Development of resistance-associated mutations after sotrovimab administration in high-risk individuals infected with the SARS-CoV-2 omicron variant. JAMA. 2022;328(11):1104–1107. doi:10.1001/jama.2022.13854
  • Rockett R, Basile K, Maddocks S, et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N Engl J Med. 2022;386(15):1477–1479. doi:10.1056/NEJMc2120219
  • Vellas C, Tremeaux P, Del Bello A, et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin Microbiol Infect. 2022;28(9):1297–1299. doi:10.1016/j.cmi.2022.05.002
  • Destras G, Bal A, Simon B, Lina B, Josset L. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients. Lancet Microbe. 2022;3(8):e559. doi:10.1016/S2666-5247(22)00120-3
  • Huygens S, Oude Munnink B, Gharbharan A, Koopmans M, Rijnders B. Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 omicron variant. Clin Infect Dis. 2023;76(3):e507–e509. doi:10.1093/cid/ciac601
  • Hogan JI, Duerr R, Dimartino D, et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019. Clin Infect Dis. 2023;76(2):342–345. doi:10.1093/cid/ciac769
  • Shabardina V, Kischka T, Manske F, et al. NanoPipe-A web server for nanopore MinION sequencing data analysis. Gigascience. 2019;8:2.
  • Hirose R, Ikegaya H, Naito Y, et al. Survival of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus on human skin: importance of hand hygiene in coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73(11):e4329–e4335. doi:10.1093/cid/ciaa1517
  • Vanderheiden A, Edara VV, Floyd K, et al. Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol. 2020;131(1):e116. doi:10.1002/cpim.116
  • Takashita E, Yamayoshi S, Fukushi S, et al. Efficacy of antiviral agents against the omicron subvariant BA.2.75. N Engl J Med. 2022;387(13):1236–1238. doi:10.1056/NEJMc2209952
  • Ikemura N, Taminishi S, Inaba T, et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 omicron variant and confers protection against infection in vivo. Sci Transl Med. 2022;14(650):eabn7737. doi:10.1126/scitranslmed.abn7737
  • Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–3108. doi:10.1016/j.cell.2021.05.005
  • Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021;184(15):3949–3961 e11. doi:10.1016/j.cell.2021.06.002
  • Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. doi:10.1001/jama.2021.0202
  • Stevens LJ, Pruijssers AJ, Lee HW, et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14(656):eabo0718. doi:10.1126/scitranslmed.abo0718
  • Szemiel AM, Merits A, Orton RJ, et al. In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 2021;17(9):e1009929. doi:10.1371/journal.ppat.1009929
  • Checkmahomed L, Carbonneau J, Du Pont V, et al. In vitro selection of remdesivir-resistant SARS-CoV-2 demonstrates high barrier to resistance. Antimicrob Agents Chemother. 2022;66(7):e0019822. doi:10.1128/aac.00198-22
  • Heyer A, Gunther T, Robitaille A, et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep Med. 2022;3(9):100735. doi:10.1016/j.xcrm.2022.100735
  • Gandhi S, Klein J, Robertson AJ, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13(1):1547. doi:10.1038/s41467-022-29104-y
  • N’Guessan A, Kailasam S, Mostefai F, et al. Selection for immune evasion in SARS-CoV-2 revealed by high-resolution epitope mapping combined with genome sequence analysis. biorxiv. 2022. doi:10.1101/2022.06.01.494373
  • Mishra D, Suri GS, Kaur G, Tiwari M. Comparative insight into the genomic landscape of SARS-CoV-2 and identification of mutations associated with the origin of infection and diversity. J Med Virol. 2021;93(4):2406–2419. doi:10.1002/jmv.26744
  • Wu C, Qavi AJ, Hachim A, et al. Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. iScience. 2021;24(6):102681. doi:10.1016/j.isci.2021.102681

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.